Meyka Pro banner
Metsera, Inc.

Metsera, Inc. Fundamental Analysis (NASDAQ: MTSR)

MTSR●NASDAQ
HealthcareBiotechnology
$70.50
$0.25(0.35%)
U.S. Market opens in 18h 16m

Metsera, Inc. Fundamental Analysis (NASDAQ: MTSR)

Metsera, Inc. (NASDAQ: MTSR) shows weak financial fundamentals with a PE ratio of -39.83, profit margin of 0.00%, and ROE of -47.04%. The company generates N/A in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

PEG Ratio-16.63
Current Ratio4.25

Areas of Concern

ROE-47.04%
Operating Margin0.00%
We analyze MTSR's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -23.9/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-23.9/100

We analyze MTSR's fundamental strength across five key dimensions:

Efficiency Score

Weak

MTSR struggles to generate sufficient returns from assets.

ROA > 10%
-32.58%

Valuation Score

Excellent

MTSR trades at attractive valuation levels.

PE < 25
-39.83
PEG Ratio < 2
-16.63

Growth Score

Weak

MTSR faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Excellent

MTSR maintains a strong and stable balance sheet.

Debt/Equity < 1
0.01
Current Ratio > 1
4.25

Profitability Score

Weak

MTSR struggles to sustain strong margins.

ROE > 15%
-4703.51%
Net Margin ≥ 15%
0.00%
Positive Free Cash Flow
No

Key Financial Metrics

Is MTSR Expensive or Cheap?

P/E Ratio

MTSR trades at -39.83 times earnings. This suggests potential undervaluation.

-39.83

PEG Ratio

When adjusting for growth, MTSR's PEG of -16.63 indicates potential undervaluation.

-16.63

Price to Book

The market values Metsera, Inc. at 21.96 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

21.96

EV/EBITDA

Enterprise value stands at -42.59 times EBITDA. This is generally considered low.

-42.59

How Well Does MTSR Make Money?

Net Profit Margin

For every $100 in sales, Metsera, Inc. keeps $0.00 as profit after all expenses.

0.00%

Operating Margin

Core operations generate 0.00 in profit for every $100 in revenue, before interest and taxes.

0.00%

ROE

Management delivers $-47.04 in profit for every $100 of shareholder equity.

-47.04%

ROA

Metsera, Inc. generates $-32.58 in profit for every $100 in assets, demonstrating efficient asset deployment.

-32.58%

Following the Money - Real Cash Generation

FCF Per Share

Each share generates $-1.34 in free cash annually.

$-1.34

FCF Yield

MTSR converts -1.90% of its market value into free cash.

-1.90%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-39.83

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-16.63

vs 25 benchmark

P/B Ratio

Price to book value ratio

21.96

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.00

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.008

vs 25 benchmark

Current Ratio

Current assets to current liabilities

4.25

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.47

vs 25 benchmark

ROA

Return on assets percentage

-0.33

vs 25 benchmark

ROCE

Return on capital employed

-0.42

vs 25 benchmark

How MTSR Stacks Against Its Sector Peers

MetricMTSR ValueSector AveragePerformance
P/E Ratio-39.8331.29 Better (Cheaper)
ROE-47.04%543.00% Weak
Net Margin0.00%8965.00% Weak
Debt/Equity0.010.51 Strong (Low Leverage)
Current Ratio4.255.79 Strong Liquidity
ROA-32.58%-96.00% (disorted) Weak

MTSR outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Metsera, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ